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Are we over oxidized?
A number of recent clinical trials with antioxidants, notably
vitamin C and E, have provided no support for the commonly
held view that increasing our intake of antioxidants will
offset the ravages of cardiovascular disease as well as other
diseases (for extensive critical reviews see: Kritharides and
Stocker 2002; Antoniades et al 2003; Touyz 2004). Is this
conclusion justified? The role of antioxidant dietary adjuncts
and therapy in prevention and treatment remains a highly
important clinical question. In this opinion article we address
the question: Is there a future for antioxidant therapy in the
treatment and prevention of cardiovascular disease? We
conclude that there is a need for better-designed studies as
well as a re-thinking of the choice of antioxidants.
What is oxidative stress?
There is considerable literature that indicates that the
excessive production of reactive oxygen species (ROS) leads
to oxidative stress and the oxidation of biological
macromolecules. Oxidative stress is defined as an increase
in ROS and/or a decrease in the antioxidant defence
mechanisms. Endogenous antioxidants include glutathione
peroxidase and CuZn superoxide dismutase (CuZnSOD).
Oxidative stress is an important contributory factor to the
etiology of many cardiovascular diseases, including
atherosclerosis, diabetes, heart failure, and hypertension.
An important target for ROS in the pathological cascade is
the endothelium, and endothelial dysfunction is increasingly
being recognized as an important indicator of the health of
the cardiovascular system (Dusting and Macdonald 1995;
Cai and Harrison 2000; Verma and Anderson 2002; Triggle
et al 2003). It has been said, “a man is only as old as his
endothelium” (Ding and Triggle 2005, p 57).
What do we understand by ROS?
ROS are a family of molecules, including molecular oxygen
and its derivatives, which are produced in all aerobic cells
through a variety of enzymic processes (Ellis and Triggle
2003; Jiang et al 2004). Many species of ROS possess
unpaired electrons and thus are free radicals – these include
superoxide anion (￿O2
–), hydroxyl radical (￿OH), and the
free radical form of nitric oxide (￿NO). Other members of
the ROS family include hydrogen peroxide (H2O2) and
peroxynitrite (ONOO–). Although the important biological
functions of NO are well known, it is also now increasingly
being realized that other ROS also contribute to
physiological and cell signaling pathways (for review see
Dröge 2002).
Why does an elevation of ROS lead to
cardiovascular disease?
The overproduction of ￿O2
– will be detrimental because of
the rapid interaction of ￿O2
– with nitric oxide (NO), which
leads to the loss of NO bioavailability, an increase in the
production of peroxynitrite (ONOO–), a subsequent
reduction in the vascular effects of NO, as well as a reduction
in the antiatherogenic effects of NO. Oxidation of low-
density lipoprotein (LDL) leads to lipid peroxidation, which
is a major contributor to atherosclerosis and cardiovascular
dysfunction. An elevation of ￿O2
– will also lead to the
oxidation of the important co-factor in the regulation of nitric
oxide synthase, tetrahydrobiopterin (BH4), and this will lead
to an “uncoupled eNOS”, which will then synthesize ￿O2
–
rather than NO (Pannirselvam et al 2003; Alp and Channon
2004). Clearly, if the level of NO and its bioavailability are
reduced, cardiovascular function will be compromised.
Elevated production of ￿O2
– may also be linked to plaque
instability (Cai and Harrison 2000; De Meyer et al 2003)
with the shoulder region of the plaque being a particularly
active area for ￿O2
– production (Sorescu et al 2002). Patients
with endothelial dysfunction and in whom arterial ￿O2
–
production is also elevated are at highest risk for vascular
morbidity and mortality (Guzik et al 2000; Heitzer et al
2001; for review see Channon and Guzik 2002). In diabetes,
where cardiovascular disease is of particular concern, there
are multiple sources of ROS including the auto-oxidationVascular Health and Risk Management 2005:1(2) 94
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of glucose, increased substrate flux, and decreased levels
of NADPH through the polyol pathway. Formation of
advanced glycation end (AGE) products and their interaction
with cellular targets, such as endothelial cells, may lead to
oxidative stress and promote formation of oxidized LDL.
Several enzyme systems are known to be sources of ROS
including the mitochondrial respiratory chain, xanthine
oxidase, NADPH oxidase, cyclooxygenase, cytochrome
P450, and uncoupled eNOS (Ellis and Triggle 2003).
Brownlee’s group (Nishikawa, Edelstein, Brownlee 2000;
Nishikawa, Edelstein, Du, et al 2000) have argued that
mitochondria are the source of ROS and that uncoupling,
for instance, of oxidative phosphorylation in endothelial
cells under high glucose conditions, prevents the sequelae
of hyperglycemia. The work described by Nishikawa and
colleagues (2000) was performed using cell culture protocols
but cell culture conditions per se may result in oxidative
stress (Halliwell 2003). Therefore, these data need to be
reproduced in functional vascular preparations before
conclusions can begin to be translated to clinical conditions.
There is also growing evidence that NADPH oxidase is a
major source of vascular superoxide production (Griendling
et al 2000; Jiang et al 2004). For example, increased activity
of NADPH oxidase makes an important contribution to the
pathogenesis of experimental models of vascular disease,
including intimal hyperplasia induced by periarterial collars
(Paravicini et al 2002) and arterial balloon injury (Souza et
al 2000; Chen et al 2004), cholesterol-induced athero-
sclerosis (Warnholtz et al 1999), vein graft intimal
hyperplasia (West et al 2001), and hypertension (Zalba et al
2000). Gene disruption of the p47phox component of
NADPH oxidase has been shown to significantly reduce
superoxide production by vascular smooth muscle cells and,
importantly, to reduce the development of atherosclerotic
lesions (Barry-Lane et al 2001). A crucial clinical link was
shown by Guzig et al (2000), who found that increased
superoxide generation by NADPH oxidase in vessels was
strongly associated with risk factors for atherosclerosis and
impaired endothelial NO function in patients with coronary
artery disease. In addition, there is experimental evidence
that shows unambiguously that blocking NADPH oxidase-
mediated generation of superoxide leads to regression or
amelioration of vascular disease. Pharmacological and gene
targeting strategies for NADPH oxidase have been found to
lower blood pressure (Touyz 2004) and regress or reduce
vascular remodeling (Barry-Lane et al 2001; Chen et al 2004;
Dusting et al 2004). Intuitively, increasing antioxidant intake
should therefore prove beneficial for cardiovascular disease.
So why then are the data from epidemiological
and clinical studies with antioxidants often
confusing and contradictory?
The data from intervention studies in humans with
antioxidants, notably vitamin C and/or vitamin E
(tocopherols), may simply reflect that the interventions
produced variable reductions in oxidative stress in a highly
heterogeneous population (see Antoniades et al 2003). Many
epidemiological and observational studies have provided
support for the concept that a diet rich in antioxidants,
despite exposure to other cardiovascular risk factors such
as dietary fat, is associated with lower incidences of
cardiovascular events (Gey et al 1991). Similarly for animal
studies – although the data for vitamin E supplementation
is open to other interpretations (Upston et al 1999). To take
such data and design an appropriate prospective study is
not an easy task. Unfortunately, several large prospective
randomized intervention studies have failed to provide
support for the benefit of antioxidants. Thus, the HOPE study
with vitamin E (Lonn et al 2002; Mann et al 2004) and
another study with vitamin C, vitamin E, and β-carotene
(Heart Protection Study Collaborative Group 2002) reported
no benefit for patients with diabetes and cardiovascular
disease. In both these studies, plasma concentrations of the
vitamins as well as the lipid profile were measured and
reported, but surprisingly, no measure was made of oxidative
stress. Thus, in neither study was it possible to conclude
whether the interventions actually modified oxidative stress
in the patients; somewhat akin, as noted by Halliwell (2000),
to conducting a trial with antihypertensive drugs but not
monitoring blood pressure. Although it can be argued that
there is no clear agreement as to which biomarkers best
monitor oxidative stress, the measurement of, for instance,
the isoprostanes as an indicator of lipid peroxidation would
have provided one reference set of data (see Griendling and
FitzGerald 2003; Halliwell and Whiteman 2004). In
addition, the choice of vitamins C and E may not have been
the best antioxidants to include in the trials (they do not
greatly affect isoprostane levels) (Levine et al 2001;
Meagher et al 2001), although their inclusion was probably
based on their ready availability in dietary sources. Vitamin
E is associated with the lipophilic/hydrophobic domains of
lipoproteins and cell membranes, and ROS are generated in
the cytosolic and extracellular compartments – perhaps they
never meet (Touyz 2004)? Furthermore, it is doubtful
whether any of the classical antioxidants are capable of
preventing the reaction of superoxide with NO, for this is
one of the fastest known “biological” reactions (rate constantVascular Health and Risk Management 2005:1(2) 95
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6.7 × 109 mol–1 . s–1; Huie et al 1993) , and is much faster than
the dismutation of superoxide by phenolics such as vitamin
E. Finally, the choice of the patient population selected for
these trials may be questioned. If you are going to study the
effects of antioxidant therapy would it not be best to choose
a population group with demonstrated high levels of
oxidative stress?
If vitamin C and E are not the ideal antioxidants,
then what should be used?
Much recent press has been given to ubiquinone, or
coenzyme Q10, which has been described as a “powerful
antioxidant” and, because it is a critical intermediate of the
mitochondrial electron transport chain, can be readily linked
to a mitochondrial dysfunction and elevated NADH and
NADPH oxidase activity (see Chew and Watts 2004). Indeed
oral coenzyme Q10 improves brachial artery endothelial
function in patients with dyslipidemia and type 2 diabetes
(Watts et al 2002). These data are potentially of significance
as the basis for intervention strategies in so far as they have
been interpreted as reflecting a “targeted correction” of the
cellular basis of oxidative stress. Is this a correct conclusion?
The answer is “probably not”, as more studies are clearly
required to directly demonstrate the link between coenzyme
Q10 treatment, improvement of endothelial function, and an
action on the mitochondrial electron transport chain.
Probucol, another so-called antioxidant that has proved
moderately successful in preventing restenosis after
coronary angioplasty (Cote et al 1999; Tardif et al 2003),
also lowers cholesterol and induces a protective
hemoxygenase enzyme (HO-1) in the artery wall (Deng et
al 2004). Its benefits, therefore, cannot be ascribed entirely
to its antioxidant properties.
Unfortunately the term “antioxidant” is widely misused,
for just about any molecule can act as an antioxidant
provided it is presented with an appropriate oxidizable
substrate. Indeed, most antioxidants can become pro-
oxidants under certain cellular circumstances – this is true
for α-tocopherol (the most active form of vitamin E), which
can be pro-oxidant and initiate tocopherol-mediated
peroxidation (Bowry et al 1992; Upston et al 1999). Electron
transfer to antioxidants can generate other free radicals that
can have their own pathophysiological actions. Moreover,
as discussed above, the reaction of NO with superoxide is
much faster than the electron transfer between superoxide
and classical antioxidants, so it is not surprising that when
superoxide and NO are present in the same cellular
compartment, antioxidants have little impact on the
pathways of oxidation.
So where do we go from here?
Potentially, blocking the source of ROS generation in
pathophysiological circumstances may be a more fruitful
approach to relieving oxidative stress and its consequences
than attempting to inactivate superoxide after it is formed.
Although there are several experimental tools that can be
used to block NADPH oxidase in vitro or even in vivo
(Brosnan 2004; Jiang et al 2004), none of the compounds
in the public domain can be considered sufficiently selective
to embark on development for clinical trial at this stage.
For anything more than acute intervention, a compound that
inactivates the NADPH oxidase system entirely could be
expected to compromise infection control, as exemplified
in chronic granulomatous disease, a genetic disorder
resulting from a defect in the key catalytic subunit of the
NADPH oxidase in leukocytes (Babior 2004). However, the
discovery that there are distinct isoforms of this crucial
membrane subunit expressed particularly in vascular cells
including endothelium (Cai et al 2003; Jiang et al 2004;
Ellmark et al 2004) opens the way to develop vascular-
specific inhibitors of the NADPH oxidase. While such
deliberately targeted compounds will become available in
the near future, it is attractive to speculate upon the reasons
why the most successful cardiovascular drugs of recent times
(ACE inhibitors, angiotensin AT1 receptor blockers, and
HMGCoA reductase inhibitors) have all been proven to
greatly improve morbidity and mortality outcomes in large
multicentre trials. All of these drugs indirectly reduce the
activity of NADPH oxidase (Jiang et al 2004), because
angiotensin II, acting through AT1 receptors, is a well known
activator of the vascular NADPH oxidase (Cai et al 2003),
and statins also block activation of the enzyme complex by
the Rac subunit (Wagner et al 2000). Perhaps fortuitously,
these powerful therapeutics are treating the underlying cause
of vascular disease – oxidative stress. In the meantime, there
is scope for a fuller elucidation of the pathways that lead to
oxidative stress and the description and pharmacological
characterization of powerful antioxidants that can be used
in improved clinical trials. We can then answer the question:
Are we over oxidized?
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